A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria(CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihistamines
- Conditions
- Chronic Inducible UrticariaMedDRA version: 20.0Level: PTClassification code: 10052568Term: Urticaria chronic Class: 100000004858Therapeutic area: Diseases [C] - Immune System Diseases [C20]Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- CTIS2023-507534-24-00
- Lead Sponsor
- Jasper Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Written informed consent after the nature of the trial has been fully explained and before performing any trial related assessments, Males and females, =18 years old, Diagnosis of ColdU or SD despite the use of H1-antihistamines as defined by all of the following: Diagnosis of ColdU or SD for = 3 months, symptoms must comprise both wheal and itch or painful sensation; Presence of itch and hives for = 6 consecutive weeks at any time prior to Screening despite current use of H1-antihistamines (as reported by the participant); ColdU participants must have a positive cold stimulation test above 4ºC using TempTests® (wheal and itch or painful sensation) on site during Screening using TempTest® to be eligible; SD participants must have a positive FricTests® with = 3 pins (wheal and itch) on site during Screening to be eligible., Use of H1-antihistamines on stable dose up to four-fold of the approved dose for at least 4 weeks prior to the Screening visit and not expected to change during first 12 weeks of the trial, Participants with chronic spontaneous urticaria (CSU) are eligible if they present with symptoms consistent with ColdU or SD and ColdU or SD is the dominant type of chronic urticaria, Blood counts at Screening with: Hemoglobin: = 11 g/dl; Platelets: = 100,000/mm3; Leucocytes: = 3,000/mm3; Neutrophils: = 2,000/mm3, Willing and able to participate and adhere to the trial visit schedule
Women who are pregnant or nursing or intend to become pregnant during the course of the trial., Electrocardiogram (ECG) findings at Screening that are considered clinically significant., Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x Upper limit of normal (ULN) at Screening, Serum total bilirubin >1.5 x ULN, unless attributable to Gilbert’s syndrome., Estimated creatinine clearance (eCrCl) by Cockcroft-Gault equation using total body weight < 60 mL/min., Known HIV, hepatitis B, hepatitis C infection, or acute/long-COVID., Major abdominal or thoracic surgery within 8 weeks prior to Screening or planned surgery during trial participation, Male participants (who are not vasectomized) who are not willing to use highly effective contraceptive methods (when having sexual intercourse with a female partner of childbearing potential and who are not willing to abstain from sperm donation during the trial and for at least 150 days after last IP dosing. A male participant is considered vasectomized if he had a vasectomy at least 4 months prior to Screening and if he has received post-surgical medical assessment of the surgical success of the vasectomy., Female participants of childbearing potential not willing to use highly effective contraceptive methods during the trial and for at least 150 days after IP dosing in case of early withdrawal). Women of non-childbearing potential, must be surgically sterile (i.e., had undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or be in menopausal state (at least 1 year without menses)., Participation in another research trial involving the use of IP within the last 30 days (or 5 half-lives of IP, whichever is longer) prior to Screening., Any known contraindications or hypersensitivity to any component of IP, drugs of similar chemical classes (i.e., to murine, chimeric or human antibodies) or antihistamines or leukotrienes., Participants who weigh less than 40 kg or more than 125 kg at Screening., Any other acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation or IP administration or could interfere with the interpretation of trial results and, in the judgment of the Investigator, would make the participant inappropriate for entry into the trial, Participants not willing to abstain from blood donations while being on the trial (Screening to EOT)., Close affiliation with the Investigator (e.g., a close relative, financially dependent on the trial site) or participant who is an employee of the Sponsor’s company., Dominant comorbid chronic urticaria with a clearly defined predominant or sole trigger (chronic inducible urticaria) other than ColdU or SD, including, heat-, solar-, pressure-, delayed pressure-, aquagenic-, cholinergic-, or contact urticaria as well as variants of cold induced urticaria or familial cold autoimmune syndrome, except CSU (see inclusion criterion #5), Other active diseases with possible symptoms of urticaria, wheals or angioedema, including urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema (e.g., due to C1 inhibitor deficiency)., Any other active skin disease associated with chronic itching that might confound the trial evaluations and results in the opinion of the Investigator (e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.).,
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: Evaluate the safety and tolerability of a single dose of briquilimab in patients with Cold Urticaria (ColdU) or Symptomatic Dermographism (SD) who remain symptomatic despite the use of H1 antihistamines.;Secondary Objective: Evaluate the preliminary efficacy of briquilimab, Evaluate the pharmacokinetic (PK) profile of briquilimab;Primary end point(s): Incidence and severity of treatment emergent AEs/SAEs, Laboratory assessments, ECG, vital signs, Supervision of expected AEs: Taste change assessments Hair color change assessment
- Secondary Outcome Measures
Name Time Method Secondary end point(s):Provocation testing: ColdU: Critical temperature threshold (CCT) SD: Critical friction threshold (CFT);Secondary end point(s):Urticaria Control Test (UCT);Secondary end point(s):Complete response rate: Proportion of participants who are urticaria free based on UCT = 16;Secondary end point(s):Well-controlled rate: Proportion of participants who are well controlled based on UCT = 12;Secondary end point(s):Time to complete response or well-controlled disease;Secondary end point(s):Time to relapse;Secondary end point(s):Serum PK concentration of briquilimab over time - Modelled serum PK parameters of briquilimab including but not limited to Cmax, Cmin and AUC as appropriate